The well being care trade will proceed to be reworked by the function of Big Data, DexCom CEO Kevin Sayer informed CNBC’s Jim Cramer on Wednesday.
“This entire integration of well being care knowledge is actually going to be the subsequent frontier,” Sayer mentioned in an interview on “Mad Money.”
Sayer’s remarks come days after a deal between Alphabet subsidiary Google and hospital community Ascension was revealed, sparking privateness considerations. First stated by The Wall Street Journal, the deal gave 150 Google workers entry to knowledge on tens of hundreds of thousands of sufferers with out their information or consent.
CNBC later reported that the partnership is certain by an trade-customary settlement that restricts how Google can make the most of the data it has collected. It can not, for instance, use it to promote focused promoting.
Nonetheless, the response to the deal between Google and Ascension represents the newest hiccup round privateness for big know-how corporations as they broaden into the well being care area.
However Sayer, whose firm has partnered with Alphabet, stays bullish on the potential for expertise and knowledge to proceed altering health care, pointing to the success Dexcom has already had.
DexCom, primarily based in San Diego, is a medical machine firm that makes a speciality of the therapy of diabetes. Specifically, it makes a machine that gives close to actual-time glucose monitoring, and not using a finger prick.
DexCom’s inventory is up 69.37% for the year, closing at $202.90 on Wednesday. It beat on every of the highest and backside traces in its most up-to-date earnings report, whereas additionally elevating income steering for the yr.